Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Lenvatinib + Pembrolizumab for Pancreatic Cancer
Recruiting3 awardsPhase 2
Duarte, California
This trial studies the effects of lenvatinib and pembrolizumab in patients with advanced pancreatic cancer that cannot be surgically removed. Lenvatinib blocks proteins needed for cancer growth, and pembrolizumab boosts the immune system to attack the cancer. The goal is to see if this combination can help control the disease.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service